<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The presence of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> has been shown to be predictors of <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>In a cross-sectional clinical study, we investigated the association of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> with asymptomatic lacunar <z:hpo ids='HP_0001297'>strokes</z:hpo> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) and we compared its significance with urinary protein markers </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We studied Japanese type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients (n=233, men=124, women=109) </plain></SENT>
<SENT sid="3" pm="."><plain>The diagnosis of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> was made according to WHO and International <z:mp ids='MP_0002055'>Diabetes</z:mp> Federation (IDF) criteria </plain></SENT>
<SENT sid="4" pm="."><plain>Cardiovascular events were recorded and asymptomatic lacunar lesions were evaluated with magnetic resonance imaging (MRI) </plain></SENT>
<SENT sid="5" pm="."><plain>We also measured urinary levels of albumin, type IV collagen, beta2-microglobulin (beta2MG), N-<z:chebi fb="9" ids="46887">acetyl</z:chebi>-beta-d-glucosaminidase (NAG) and lipocalin-type <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> D synthase (PGDS) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The prevalence of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is 31.3% (IDF) and 52% (WHO) in 233 patients and <z:mp ids='MP_0002959'>microalbuminuria</z:mp> was present in 62 subjects (26.6%) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> (WHO) significantly associated with asymptomatic lacunar lesions (p=0.035, OR=2.854, CI 1.075-7.579), while <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (IDF) or urinary markers failed to associate with presence of asymptomatic lacunar lesions </plain></SENT>
<SENT sid="8" pm="."><plain>The presence of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> or <z:mp ids='MP_0002959'>microalbuminuria</z:mp> did not show significant association with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>; however, the elevation of beta2MG, NAG and PGDS showed significant association with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>By a logistic regression analysis using urinary proteins as independent variables, the presence of higher PGDS excretion independently associated with history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> (p=0.025, OR=3.847, CI 1.180-12.545) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients, the elevation of urinary PGDS secretion closely associated with cardiovascular events and may be a supplemental or additional marker to the criteria of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
</text></document>